Biogen Inc

BIIB

$267.07

-20.11% (1 year change)

Avg closing price

Price range

Market Cap

$41.2 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$3.38 Billion

Total revenue in the last quarter.

Net Income

$702 Million

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$24.80

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

10.29x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$1.04 Billion

Earnings before interest expenses and taxes in the last quarter.

Employees

7,300

The number of full time employees.

Revenue & Earnings

Balance Sheet

Biogen Inc

At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.

News

Oppenheimer Stick to Their Buy Rating for Biogen By Investing.com

Oppenheimer Stick to Their Buy Rating for Biogen By Investing.com

Oppenheimer Stick to Their Buy Rating for Biogen

Investing.com Investing.com, 2 days ago
The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs

The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs

Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week's news flow was fairly light. The American Association of Cancer Resear...

Benzinga Benzinga, 5 days ago
Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out

Sage-Biogen Essential Tremor Candidate Hits Primary Endpoint Goal, But 38% Of People Drop Out

Sage Therapeutics Inc (NASDAQ: SAGE ) and Biogen Inc (NASDAQ: BIIB ) have scored their first but narrow win after signing their $3.1 billion deal last year in November . SAGE-324, the second major ...

Benzinga Benzinga, 10 days ago